Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity
- PMID: 22002321
- DOI: 10.1039/c1cc15638a
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity
Abstract
The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
 
        